<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4102">
  <stage>Registered</stage>
  <submitdate>25/09/2013</submitdate>
  <approvaldate>25/09/2013</approvaldate>
  <nctid>NCT01953081</nctid>
  <trial_identification>
    <studytitle>A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance</studytitle>
    <scientifictitle>A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>0082</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Enteral Feeding Intolerance</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - TD-8954
Treatment: drugs - Metoclopramide

Experimental: TD-8954 - TD-8954 single infusion for 1 hour and 4 injections of saline every 6 hours

Active Comparator: Metoclopramide - Metoclopramide 4 doses every 6 hours for 24 hours and 1 hour infusion of saline


Treatment: drugs: TD-8954


Treatment: drugs: Metoclopramide


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Adverse Events - the number of subjects reporting adverse events by treatment group</outcome>
      <timepoint>6 Days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Tmax - Time to maximal concentration in plasma</outcome>
      <timepoint>72 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Gastric Retention by Scintigraphy - Number of subjects with retention less than 13% at 180 minutes after dosing.</outcome>
      <timepoint>180 minutes</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AUC - Area under the plasma concentration time curve from 0 to 72 hours after dosing.</outcome>
      <timepoint>72 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cmax - Maximum plasma concentration</outcome>
      <timepoint>72 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Gastric Emptying by Breath Test - Time to 1/2 gastric emptying by breath test</outcome>
      <timepoint>180 minutes</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Intubated, on mechanical ventilation, and anticipated to remain on mechanical
             ventilation for 2 days after enrollment into the study

          -  Receiving enteral feeding and assessed to have developed EFI, as defined by a GRV
             measurement =250 mL within the 24 hours before randomization</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of diabetic or idiopathic gastroparesis

          -  Screening blood glucose &gt;15 mmol/L (270 mg/dL) while receiving insulin

          -  Impaired renal function, as defined by estimated glomerular filtration rate (eGFR) &lt;30
             mL/min, as determined by the Cockcroft-Gault formula -Bilirubin concentration in blood
             &gt;2 times the upper limit of normal

          -  ALT or AST &gt;3 times upper limit of normal

          -  Alkaline phosphatase &gt;2 times upper limit of normal

          -  Contraindication to enteral feeding

          -  Opioid or other drug overdose as the primary reason for admission to Intensive Care
             Unit (ICU)

          -  Receipt of a drug that can be used as a gastric prokinetic agent

          -  Receipt of agents known to directly influence the 5 HT4/acetylcholine prokinetic
             mechanism</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>13</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <postcode> - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Theravance Biopharma R &amp; D, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is being conducted to evaluate the safety, tolerability and early efficacy of IV
      TD 8954 compared to metoclopramide in critically ill subjects, aged 18 to 85 years, who are
      admitted to the intensive care require mechanical ventilation, and are intolerant to enteral
      feeding.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01953081</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Daniel Canafax, PharmD, FCCP</name>
      <address>Theravance Biopharma, US, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>